Another powerful future application of our work is to help discriminate rare variants that are hard to distinguish from the diseases studied here, for example FTLD-MAPT-NOS cases or cases that are difficult to discriminate as either PSP or CBD. The gene discussed is MAPT; the disease is supranuclear palsy, progressive, 1.